journal
https://read.qxmd.com/read/38527259/metastatic-melanoma-treatment-in-special-populations
#21
JOURNAL ARTICLE
Madeline Miceli, Christina Boatwright, Janice M Mehnert
This review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These specific treatment populations were excluded from the original clinical trials, which studied immune checkpoint inhibitors and BRAF/MEK inhibitors in the advanced melanoma setting. We have synthesized the current body of literature, mainly case series and retrospective analyses, to reflect the evidence for the treatment of these special patient populations at present...
March 2024: Cancer Journal
https://read.qxmd.com/read/38527258/treatment-of-stage-iii-resectable-melanoma-adjuvant-and-neoadjuvant-approaches
#22
JOURNAL ARTICLE
Ahmad A Tarhini, Ella Castellano, Islam Eljilany
Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-lymphocyte antigen 4 ipilimumab at 10 mg/kg compared with placebo and ipilimumab 3 mg/kg compared with high-dose interferon α...
March 2024: Cancer Journal
https://read.qxmd.com/read/38527257/a-general-approach-to-patients-presenting-with-locally-advanced-or-distant-metastatic-disease
#23
JOURNAL ARTICLE
James W Smithy, Paul B Chapman
The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a broad overview on the use of these agents in the first-line setting, incorporating a review of the clinical literature as well as the practice patterns of our respective melanoma groups. Throughout, we highlight areas of uncertainty that provide opportunities for future clinical investigation and additional improvement in outcomes for patients with melanoma...
March 2024: Cancer Journal
https://read.qxmd.com/read/38527256/how-far-we-ve-come
#24
JOURNAL ARTICLE
Mario Sznol, Jeffrey S Weber
No abstract text is available yet for this article.
March 2024: Cancer Journal
https://read.qxmd.com/read/38265926/telehealth-and-technology-new-directions-in-cancer-care
#25
JOURNAL ARTICLE
James Yu, Carolyn Petersen, Sonya Reid, S Trent Rosenbloom, Jeremy L Warner
Telehealth is a broad concept that refers to any delivery of health care in real time using technologies to connect people or information that are not in the same physical location. Until fairly recently, telehealth was more aspiration than reality. This situation changed radically due in part to the COVID-19 pandemic, which led to a near-overnight inability for patients to be seen for routine management of chronic health conditions, including those with cancer. The purpose of this brief narrative review is to outline some areas where emerging and future technology may allow for innovations with specific implications for people with a current or past diagnosis of cancer, including underserved and/or historically excluded populations...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265925/digital-health-for-oncological-care
#26
JOURNAL ARTICLE
Adam B Cohen, Lee H Schwamm
Digital health tools extend well beyond telemedicine, holding great potential to advance oncological care. We survey digital health and provide recommendations across the health continuum, tailoring them to oncology, including prevention, detection and diagnosis, and treatment and monitoring. Within the prevention realm, we review wellness technologies, cancer screening, mental health solutions, and digital biomarkers. For detection and diagnosis, we describe existing and emerging solutions for remote patient monitoring and various means to capture digital biomarkers, the "digital exam," and "digital outcomes...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265924/telemedicine-and-burnout-how-enhancing-operational-support-can-improve-digital-health-tools
#27
JOURNAL ARTICLE
Debra Patt, Colleen O'Neill
During the COVID-19 pandemic, there was an unprecedented growth in telemedicine due to the need to provide safe access to care during a global pandemic. The regulatory, compliance, and payment policy landscape favorably changed, paving the way for growth in utilization. Despite these favorable changes in the landscape, operational and technical burdens remained barriers to optimal use of telemedicine. Investments in operational processes and vendor selection can improve the patient and clinician experience in using telemedicine, so this digital tool can diminish burnout...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265923/supportive-care-for-cancer-patients-via-telehealth-breaking-bad-news-and-providing-palliative-care-virtually
#28
JOURNAL ARTICLE
Tara E Soumerai, Therese M Mulvey, Vicki A Jackson, Inga T Lennes
Delivering oncologic care via telemedicine has presented a unique set of benefits and challenges. Discussions of sensitive topics between patients and providers can be difficult on a virtual platform. Although it was imperative to utilize telemedicine to keep cancer patients safe during the height of the pandemic, its continued use in the postvaccination era has provided important conveniences to both providers and patients. In the case of breaking bad news and end-of-life discussions, however, in-person care has remained the overwhelming preference of both groups...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265922/telemedicine-and-cancer-clinical-research-opportunities-for-transformation
#29
JOURNAL ARTICLE
Mitchell S von Itzstein, Mary E Gwin, Arjun Gupta, David E Gerber
Telemedicine represents an established mode of patient care delivery that has and will continue to transform cancer clinical research. Through telemedicine, opportunities exist to improve patient care, enhance access to novel therapies, streamline data collection and monitoring, support communication, and increase trial efficiency. Potential challenges include disparities in technology access and literacy, physical examination performance, biospecimen collection, privacy and security concerns, coverage of services by insurance, and regulatory considerations...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265921/telehealth-and-outcomes-in-patients-with-cancer-data-and-innovation
#30
JOURNAL ARTICLE
Michael J Grant, Ann C Chiang
Despite that telehealth has been crucial to the delivery of oncology care during the COVID-19 pandemic, the impact of this care delivery mechanism on outcomes in cancer care has not been rigorously studied relative standard in-person care for patients with cancer. Patient-centered outcomes such as quality of life, patient satisfaction, and symptoms are important outcomes that have been the primary focus of many of the existing studies in this space, yet only a select few have evaluated overall survival and other objective efficacy endpoints...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265920/telemedicine-and-cancer-care-barriers-and-strategies-to-optimize-delivery
#31
JOURNAL ARTICLE
Sahil D Doshi, Erin M Bange, Bobby Daly, Gilad Kuperman, Katherine S Panageas, Michael J Morris
Telemedicine holds the potential to transform cancer care delivery and optimize value, access, and quality of care. A transformed regulatory environment coupled with the need to continue medical care despite operational limitations led to the rapid expansion of telemedicine in cancer care during the COVID-19 pandemic. Its utilization has since varied, and it has faced significant challenges. In this review, we will explore the state of telemedicine in cancer care delivery, the challenges it faces, and strategies to enhance its successful implementation...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265919/telehealth-in-cancer-care-inequities-barriers-and-opportunities
#32
JOURNAL ARTICLE
Ana Maria Lopez
Telecommunications technology began to be integrated into health care delivery by the mid-1900s, with the goal of increasing access to care including access to cancer care.There have been at least 3 significant telehealth expansion periods, with the most recent related to the COVID-19 pandemic. Technology uptake increased in the 1990s as quality improved, costs came down, and usability factors were addressed. As telehealth practice transitioned to use of personal devices, the COVID-19 pandemic arose, and necessity compelled widespread telehealth uptake...
January 2024: Cancer Journal
https://read.qxmd.com/read/38265918/telemedicine-and-cancer-shifting-a-paradigm-of-care
#33
JOURNAL ARTICLE
Anne C Chiang
No abstract text is available yet for this article.
January 2024: Cancer Journal
https://read.qxmd.com/read/37963370/primary-prevention-of-cancer-a-multilevel-approach-to-behavioral-risk-factor-reduction-in-racially-and-ethnically-minoritized-groups
#34
JOURNAL ARTICLE
Sherri Sheinfeld Gorin, Kelly Hirko
Cancer continues to be the second most common cause of death in the United States. Racially and ethnically minoritized populations continue to experience disparities in cancer prevention compared with majority populations. Multilevel interventions-from policy, communities, health care institutions, clinical teams, families, and individuals-may be uniquely suited to reducing health disparities through behavioral risk factor modification in these populations. The aim of this article is to provide a brief overview of the evidence for primary prevention among racially and ethnically minoritized subpopulations in the United States...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963369/disparities-in-gynecologic-cancers
#35
JOURNAL ARTICLE
Nita K Lee, Jasmin A Tiro, Kunle Odunsi
Gynecologic cancer disparities have different trends by cancer type and by sociodemographic/economic factors. We highlight disparities in the United States arising due to poor delivery of cancer care across the continuum from primary prevention, detection, and diagnosis through treatment and identify opportunities to eliminate/reduce disparities to achieve cancer health equity. Our review documents the persistent racial and ethnic disparities in cervical, ovarian, and uterine cancer outcomes, with Black patients experiencing the worst outcomes, and notes literature investigating social determinants of health, particularly access to care...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963368/the-promise-of-cancer-health-justice-how-stakeholders-and-the-community-can-build-a-sustained-and-equitable-system-of-cancer-care-through-the-lens-of-colorectal-cancer-interventions
#36
JOURNAL ARTICLE
Dario M Villamar, Blase N Polite
Disparities in outcomes and persistent barriers to adequate care in colorectal cancer are reflective of a system that has failed to achieve the ideals of health equity and health justice. In this review, we discuss that although much research has been done to improve upon gaps in screening, treatment, and supportive care in colorectal cancer, a concerted effort across multiple research, regulatory, and funding stakeholders with community-level organizations is essential in building a self-sustained system that effectively achieves health equity outcomes...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963367/prostate-cancer-race-and-health-disparity-what-we-know
#37
JOURNAL ARTICLE
Mack Roach, Pamela W Coleman, Rick Kittles
Prostate cancer (PCa) in African American men is one of the most common cancers with a great disparity in outcomes. The higher incidence and tendency to present with more advanced disease have prompted investigators to postulate that this is a problem of innate biology. However, unequal access to health care and poorer quality of care raise questions about the relative importance of genetics versus social/health injustice. Although race is inconsistent with global human genetic diversity, we need to understand the sociocultural reality that race and racism impact biology...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963366/diversity-and-disparities-in-lung-cancer-outcomes-among-minorities
#38
JOURNAL ARTICLE
Nyein Wint Yee Theik, Carlos Carracedo Uribe, Andres Alvarez, Meri Muminovic, Luis E Raez
Because of diversities and disparities, lung cancer incidence and mortality rates among minorities are disproportionate compared with non-Hispanic White (NHW) populations. This review focuses on the disparities in lung cancer screening, diagnosis, treatment, and outcomes that minorities, mainly Hispanic and Black, experience compared with NHW populations. Despite efforts such as improving the eligibility criteria for screening to improve lung cancer survival rates, disparities persist, particularly among minority populations...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963365/from-race-to-racism-and-disparities-to-equity-an-actionable-biopsychosocial-approach-to-breast-cancer-outcomes
#39
JOURNAL ARTICLE
Katherine Reeder-Hayes, Mya L Roberson, Stephanie B Wheeler, Yara Abdou, Melissa A Troester
PURPOSE: Racial disparities in outcomes of breast cancer in the United States have widened over more than 3 decades, driven by complex biologic and social factors. In this review, we summarize the biological and social narratives that have shaped breast cancer disparities research across different scientific disciplines in the past, explore the underappreciated but crucial ways in which these 2 strands of the breast cancer story are interwoven, and present 5 key strategies for creating transformative interdisciplinary research to achieve equity in breast cancer treatment and outcomes...
November 2023: Cancer Journal
https://read.qxmd.com/read/37963364/diversity-in-cancer-care-current-challenges-and-potential-solutions-to-achieving-equity-in-clinical-trial-participation
#40
JOURNAL ARTICLE
Kai Akimoto, Kekoa Taparra, Thelma Brown, Manali I Patel
Access to and participation in cancer clinical trials determine whether such data are applicable, feasible, and generalizable among populations. The lack of inclusion of low-income and marginalized populations limits generalizability of the critical data guiding novel therapeutics and interventions used globally. Such lack of cancer clinical trial equity is troubling, considering that the populations frequently excluded from these trials are those with disproportionately higher cancer morbidity and mortality rates...
November 2023: Cancer Journal
journal
journal
34932
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.